12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Other News

United Therapeutics, U.S. Department of Health and Human Services cardiovascular news

United Therapeutics received a subpoena from HHS's Office of Inspector General (OIG) seeking documents related to the company's marketing practices for 3 pulmonary arterial hypertension (PAH) drugs - Remodulin treprostinil, Tyvaso inhaled...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >